The FDA issued a warning letter to Similasan, leading to the removal of homeopathic eye drops from the U.S. market. The hosts speculate on the timing of this removal relative to reports of "pink eye" symptoms associated with bird flu. They also examine the stock performance of Armata Pharmaceuticals (ARMP), noting its significant decline since going public.
